nomura report target 32c, page-26

Thanks nuts,

That's encouraging to hear that Provenge got approval with a similar hazard ratio. Phase IIb is not statistically powered for such a result, and the cohort is slightly different, but hopefully we see a similar result. This will show that the CANVAS trial is appropriately powered. That is the key to the phase IIb results.

Clinically though, i wonder how long the actual duration is. What I mean here is:

If the control group progressed after 7.7 minutes, and the treatment group after 10 minutes, that would still give a hazard ratio of 0.77...but this is clearly useless.

Do you know what the actual difference in the median progression free survival time was for Provenge??